ddi

In this episode, Karen Ha, MD, explores recommendations and data on the role of NNRTIs in current practice.

Listen as she gives her perspectives on:

• DHHS guideline recommendations on the use of NNRTI-based ART
• Weight gain data from the ADVANCE study, DRIVE-AHEAD, DRIVE-FORWARD, DRIVE-SHIFT, and a multivariate analysis of weight gain on ART
• Key food effects and drug–drug interaction considerations with the use of NNRTIs

Presenter:

Karen Ha, MD
Assistant Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Cooper University Hospital
Cooper Medical School of Rowan University
Camden, New Jersey

Follow along with the slides at: 
https://bit.ly/3G2PS2p

See the entire program at:
https://bit.ly/2TXTYWx
 

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:

• DHHS, EACS, IAS, and WHO recommendations for first-line ART
• Virologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National Survey
• Polypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairment
• Cardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ART

Presenters:

Jonathan Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine  
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, Florida  

Jens D. Lundgren, MD, DMSc
Professor
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark  

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/3miT6qH

See the entire program at: 
https://bit.ly/2TXTYWx

Bienvenue chez « Ask Stago», le Podcast fournissant des réponses d'experts à vos questions d'experts en hémostase.  

Dans l'épisode d'aujourd'hui, avec François Hamon notre directeur Business Développement, nous discuterons de l’utilité de différents biomarqueurs fibrino-dépendants dans le diagnostic de coagulation intravasculaire disséminée. 

Pour en savoir plus :  

• Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. BMJ 1996; 312: 683-7 
• Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, Kitamura N, Saitoh D. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care. 2016 Sep 14;20:287 
• Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 Nov;86(5):1327-30 
• JAAM; Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, Kitamura N, Saitoh D. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care. 2016  
• Sep 14;20:287 
• Boral BM, Williams DJ, Boral LI. Disseminated Intravascular Coagulation. Am J Clin Pathol 2016; 146: 670-80 
• Wada H, Sakuragawa N. Are fibrin-related markers useful for the diagnosis of thrombosis? Semin Thromb Hemost 2008; 34: 33-8 
• Toh JMH, Ken-Drorb G, Downey D, Abram ST. The clinical utility of fibrin-related biomarkers in sepsis Blood Coagulation and Fibrinolysis 2013, 24:00–00 
• Gris JC, Cochery-Nouvellon E, Bouvier S, Jaber S, Albanese J, Constantin JM, Orban JC, Morel J, Leone M, Deras P, Elotmani L, Lavigne-Lissalde G, Lefrant JY. Clinical value of automated fibrin generation markers in patients with septic shock: a SepsiCoag ancillary study. Br J Haematol. 2018 Nov;183(4):636-647 
• (Singh N, Prasad Pati H, Tyagi S, Datt Upadhyay A, Saxena R. Evaluation of the Diagnostic Performance of Fibrin Monomer in Comparison to D-Dimer in Patients With Overt and Nonovert Disseminated Intravascular Coagulation. Clin Appl Thromb / Hemost 2015; 1-6.). 
• (Park KJ, Kwon EH, Kim HJ, Kim SH. Evaluation of the diagnostic performance of fibrin monomer in disseminated intravascular coagulation. Korean J Lab Med. 2011; 31: 143-7.). 

Le contenu est de nature scientifique et technique. Il se veut un outil pédagogique pour les professionnels de laboratoire et les sujets abordés ne sont pas destinés à être des recommandations ou des commentaires sur la pratique clinique appropriée. 

In this episode from the series “Key Decisions in HIV Care,” Milena Murray, PharmD, MSc, BCIDP, AAHIVP, and Jonah Musa, MBBS, MSCI, PhD, discuss important considerations for ART use in pregnancy, including DHHS and WHO guideline recommendations and data supporting recommended ART regimen options in pregnancy from IMPAACT 2010, Tsepamo, and DoLPHIN-2. They also discuss pharmacokinetic considerations and drug–drug interactions. Following their dialogue, the faculty field questions from healthcare professionals.

Presenters:

Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Associate Professor  
Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
HIV/ID Clinical Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois

Jonah Musa, MBBS, MSCI, PhD
Professor, Obstetrics and Gynecology
University of Jos
Honorary Consultant Obstetrician and Gynecologist
Jos University Teaching Hospital
Jos, Nigeria

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/3GRxpGQ

Link to full program:
https://bit.ly/2TXTYWx

Welcome to Ask Stago, the weekly podcast for Hemostasis laboratory professionals.   

This week, with our expert Paul Riley, Scientific Business Development Manager, Cécile Hourquet and Audrey Carlo will cover the usage of fibrin related markers in the diagnosis of disseminated intravascular coagulopathy.   

Litterature: 

• Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. BMJ 1996; 312: 683-7 
• Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, Kitamura N, Saitoh D. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care. 2016 Sep 14;20:287 
• Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 Nov;86(5):1327-30 
• JAAM; Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, Kitamura N, Saitoh D. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care. 2016 
• Sep 14;20:287 
• Boral BM, Williams DJ, Boral LI. Disseminated Intravascular Coagulation. Am J Clin Pathol 2016; 146: 670-80 
• Wada H, Sakuragawa N. Are fibrin-related markers useful for the diagnosis of thrombosis? Semin Thromb Hemost 2008; 34: 33-8 
• Toh JMH, Ken-Drorb G, Downey D, Abram ST. The clinical utility of fibrin-related biomarkers in sepsis Blood Coagulation and Fibrinolysis 2013, 24:00–00 
• Gris JC, Cochery-Nouvellon E, Bouvier S, Jaber S, Albanese J, Constantin JM, Orban JC, Morel J, Leone M, Deras P, Elotmani L, Lavigne-Lissalde G, Lefrant JY. Clinical value of automated fibrin generation markers in patients with septic shock: a SepsiCoag ancillary study. Br J Haematol. 2018 Nov;183(4):636-647 
• (Singh N, Prasad Pati H, Tyagi S, Datt Upadhyay A, Saxena R. Evaluation of the Diagnostic Performance of Fibrin Monomer in Comparison to D-Dimer in Patients With Overt and Nonovert Disseminated Intravascular Coagulation. Clin Appl Thromb / Hemost 2015; 1-6.). 
• (Park KJ, Kwon EH, Kim HJ, Kim SH. Evaluation of the diagnostic performance of fibrin monomer in disseminated intravascular coagulation. Korean J Lab Med. 2011; 31: 143-7.). 

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

You may have heard of Data-Driven Instruction (DDI). But what is Data-Driven Learning?

Data-Driven Learning will replace DDI, I predict. Why? Because today's youth need to respond entrepreneurially to the abundance of data that surrounds them. To thrive in the Information Age, they must learn to cut through the noise, discern what data matters, and respond accurately.

Data-Driven Learning is like teaching a teenager how to read the gauges on the car dashboard herself, without the adult saying one word from the shotgun seat. And that’s what parents want. We want our teens to learn how to drive that car and read the dials independently.

In this show, Michael Norton, manager of blended learning and academics at KIPP Texas, explains why Data-Driven Learning is the "handshake" to Data-Driven Instruction at his schools. He views both strategies as important.

This Tuesday we're publishing a free “Progress Power Tracker.” You can use it with your students to help them look at their data for the week, graph their results, and then analyze their results.

The tool will help you equip your learners to read and respond to their OWN data. You can use it at the elementary, middle, or high school level. You’ll find the Progress Power Tracker next Tuesday on the Tuesday Share page:

https://www.readytoblend.com/tuesdays

or in your inbox if you subscribe to Tuesday Share deliveries:

http://eepurl.com/geaExT 

Livia Macedo of DDI talks about top strategies for manufacturers to build and maintain their workforces. She also details how a manufacturer can begin building a talent supply chain. Macedo will also address the importance of having manufacturing leaders focused on Industry 4.0

Become a Professional Fun-haver and Develop Your SEO Strategy:

Do you want to recruit and retain top talent at your business? Ditch the cubicles, buy better coffee, and prepare to have a good time because creating a lively corporate culture can help attract your dream team. Aaron Hageman, Owner and CEO of Delivery Drivers, Inc., says having fun at work is the secret sauce to success. This Commander-in-Fun offers his top tips to improve your work environment. Then, if you don’t know the basics of search engine optimization, you may end up paying the proverbial idiot tax. Don’t fall victim to SEO ‘experts’ who pump up vanity metrics, but not your bottom line. Jeremiah Smith, Co-Founder and CEO of SimpleTiger breaks down the three core tenets of creating a winning digital strategy, and reveals what the SEO industry doesn’t want you to know.

• [00:00:00] Explosive Growth for the 1099 Workforce
• [00:05:58] Let's Make the Workplace Fun Again
• [00:11:30] What's Your Dedicated 'Fun' Budget?
• [00:18:21] Breaking Down the Three Tenets of SEO
• [00:25:24] Content Building Tips from an SEO Expert
• [00:33:22] SEO Industry Secrets Revealed

David Juurlink SMACC Chicago talk 'Drug Interactions That Can Kill (and How to Avoid Them)’ takes us on a journey of drug interactions, case studies, and avoidance strategies.

Juurlink starts by educating us on the two different drug-drug interactions (DDI) - effects of one drug altered by the use of another . First of which is Pharmacokinetic where by one drug alters the level of another, the second Pharmacodynamic being no change in drug levels, and uses this as a basis for his following case studies.

Juurlink speaks of the dreadful literature that is available on the thousands of drug interaction per year, stating that most information comes from case reports and volunteer studies, and suggests that majority of these interaction are avoidable.

Juurlink then goes on to discuss the findings of 4 case studies involving the following Drug-Drug Interactions and their effects on the patients.

SMX/TMP + sulfonylureas
Macrolides + digoxin
APAP + warfarin
SMX/TMP + ACEI/ARB

Juurlink provides us with a short list of trigger drugs that we should be aware of, a list of meds that warrant extra caution and list of possible safer alternatives. He also suggests that it is of the up most importance to have a good pharmacist to turn to as they are given more information on drugs interactions then physicians. And, to utilise resources such as pharmacy times - where you can get information on drug interactions at a push of the button.

Juurlink also suggests that an Informed patient is a very useful safety mechanism.